PortalPublikationenEfficacy according to biomarker status of cetuximab plus FOL...

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Links

  • Carsten Bokemeyer
  • I Bondarenko
  • J T Hartmann
  • F de Braud
  • Gunter Schuch
  • A Zubel
  • I Celik
  • M Schlichting
  • P Koralewski

Beteiligte Einrichtungen

Abstract

The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).

Bibliografische Daten

OriginalspracheEnglisch
Aufsatznummer7
ISSN0923-7534
StatusVeröffentlicht - 2011
pubmed 21228335